4D Molecular Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders
Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Gain (Loss) | Deficit | Equity | |
| Balances at December 31, 2023 | 43,075,218 | $4 | $723,136 | $16 | $(415,327) | $307,829 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 427,036 | — | 4,580 | — | — | 4,580 |
| Issuance of common stock upon public offering, net of issuance costs - February / March 2024 Public Offering Sale | 7,845,314 | 1 | 316,148 | — | — | 316,149 |
| Issuance of common stock upon ATM offering, net of issuance costs | 585,938 | — | 15,263 | — | — | 15,263 |
| Issuance of common stock - 2020 ESPP | 170,436 | — | 1,258 | — | — | 1,258 |
| Issuance of pre-funded warrant for common stock conversions | (6,310,000) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 26,116 | — | — | 26,116 |
| Vesting of common stock warrants issued for services | — | — | 66 | — | — | 66 |
| Net unrealized gain on marketable securities | — | — | — | 213 | — | 213 |
| Net loss | — | — | — | — | (160,868) | (160,868) |
| Balances at December 31, 2024 | 45,793,942 | $5 | $1,086,567 | $229 | $(576,195) | $510,606 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 319,699 | — | 984 | — | — | 984 |
| Issuance of common stock upon underwritten offering, net of issuance costs | 8,385,809 | 1 | 93,339 | — | — | 93,340 |
| Issuance of common stock upon ATM offering, net of issuance costs | 1,175,000 | — | 9,576 | — | — | 9,576 |
| Issuance of common stock - 2020 ESPP | 467,762 | — | 1,253 | — | — | 1,253 |
| Issuance of common stock - exercise of pre-funded warrants | 178,280 | — | — | — | — | — |
| Issuance of common stock - stock purchase agreement | 776,398 | — | 7,500 | — | — | 7,500 |
| Issuance of common stock - exercise of equity warrants | 508,465 | — | — | — | — | — |
| Issuance of common stock upon exercise of service warrants | 2,519 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 22,016 | — | — | 22,016 |
| Net unrealized gain on marketable securities | — | — | — | 498 | — | 498 |
| Net loss | — | — | — | — | (140,109) | (140,109) |
| Balances at December 31, 2025 | 57,607,874 | $6 | $1,221,235 | $727 | $(716,304) | $505,664 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.